These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 12855625)
1. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Iversen PL; Arora V; Acker AJ; Mason DH; Devi GR Clin Cancer Res; 2003 Jul; 9(7):2510-9. PubMed ID: 12855625 [TBL] [Abstract][Full Text] [Related]
2. c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. Sekhon HS; London CA; Sekhon M; Iversen PL; Devi GR Lung Cancer; 2008 Jun; 60(3):347-54. PubMed ID: 18096271 [TBL] [Abstract][Full Text] [Related]
3. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Devi GR; Beer TM; Corless CL; Arora V; Weller DL; Iversen PL Clin Cancer Res; 2005 May; 11(10):3930-8. PubMed ID: 15897595 [TBL] [Abstract][Full Text] [Related]
4. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. Ko YJ; Devi GR; London CA; Kayas A; Reddy MT; Iversen PL; Bubley GJ; Balk SP J Urol; 2004 Sep; 172(3):1140-4. PubMed ID: 15311058 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Devi GR; Oldenkamp JR; London CA; Iversen PL Prostate; 2002 Nov; 53(3):200-10. PubMed ID: 12386920 [TBL] [Abstract][Full Text] [Related]
6. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. London CA; Sekhon HS; Arora V; Stein DA; Iversen PL; Devi GR Cancer Gene Ther; 2003 Nov; 10(11):823-32. PubMed ID: 14605668 [TBL] [Abstract][Full Text] [Related]
7. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406 [TBL] [Abstract][Full Text] [Related]
8. c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity. Arora V; Knapp DC; Smith BL; Statdfield ML; Stein DA; Reddy MT; Weller DD; Iversen PL J Pharmacol Exp Ther; 2000 Mar; 292(3):921-8. PubMed ID: 10688605 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505 [TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications. Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235 [TBL] [Abstract][Full Text] [Related]
11. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535 [TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025 [TBL] [Abstract][Full Text] [Related]
13. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086 [TBL] [Abstract][Full Text] [Related]
14. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Chiu FL; Lin JK Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor. Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333 [TBL] [Abstract][Full Text] [Related]
16. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Singh RP; Sharma G; Dhanalakshmi S; Agarwal C; Agarwal R Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):933-9. PubMed ID: 14504208 [TBL] [Abstract][Full Text] [Related]
17. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Gokhale PC; Zhang C; Newsome JT; Pei J; Ahmad I; Rahman A; Dritschilo A; Kasid UN Clin Cancer Res; 2002 Nov; 8(11):3611-21. PubMed ID: 12429653 [TBL] [Abstract][Full Text] [Related]
19. Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction. Xiao D; Lew KL; Kim YA; Zeng Y; Hahm ER; Dhir R; Singh SV Clin Cancer Res; 2006 Nov; 12(22):6836-43. PubMed ID: 17121905 [TBL] [Abstract][Full Text] [Related]
20. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Thallinger C; Wolschek MF; Maierhofer H; Skvara H; Pehamberger H; Monia BP; Jansen B; Wacheck V; Selzer E Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4185-91. PubMed ID: 15217956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]